Onset Therapeutics Launches HYLATOPIC(TM) Emollient Foam for Atopic Dermatitis

CUMBERLAND, R.I.--(BUSINESS WIRE)--Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, today announced the FDA approval and commercial launch of HYLATOPIC™ Emollient Foam, a unique, non-steroidal prescription product indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis.

MORE ON THIS TOPIC